Native Bothrops atrox snake venom Batroxobin Protein

• Cat.No.: Batroxobin-99
• Product Overview: Batroxobin is a serin protease that reduces fibronogen levels and is originally extracted from snake venom of Bothrops Atrox.

Specification

• Species: Bothrops atrox
• Source: Snake Venom
• Description: Batroxobin is used in defibrinogenation and thrombolysis and also has an effect on c-fos gene and growth factor. Batroxobin can efficiently restrain proliferation of VSMCs, by blocking the release and uptake of Ca2+, thus influencing [Ca2+]i. Batroxobin converts fibrinogen to fibrin through the restricted release of fibrinopeptide-A from fibrinogen to promote blood to clot. Unlike thrombin, it is not affected by heparin and hirudin.
• Form: Sterile Filtered white lyophilized powder.
• Molecular Mass: 43 kDa
• Unit Definition: 100BU [Batroxobin Units]=1mg.
• Storage: Batroxobin although stable at room temperature for 3 weeks, should be stored below -18 centigrade. Upon reconstitution Batroxobin should be stored at 4 centigrade between 2-7 days and for future use below -18 centigrade. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).
  Please prevent freeze-thaw cycles.
• Storage Buffer: The Batroxobin protein was lyophilized from a concentrated (1 mg/mL) solution with no additives.
• Reconstitution: It is recommended to reconstitute the lyophilized Batroxobin in sterile 18M-cm H2O not less than 100 μg/mL, which can then be further diluted to other aqueous solutions.
• Publications:
  Contributions of thrombin targets to tissue factor‐dependent metastasis in hyperthrombotic mice (2013)

Gene Information

• Synonyms: Thrombin-like enzyme batroxobin; EC 3.4.21.74; BX; Bothrops atrox serine proteinase; Venombin-A; Defibrase; Reptilase; Batroxobin

Citation

Contributions of thrombin targets to tissue factor-dependent metastasis in hyperthrombotic mice

Journal: Journal of thrombosis and haemostasis : JTH    PubMed ID: 24175924    Data: 2014/1/1

Authors: Naho Yokota, Alessandro Zarpellon, Wolfram Ruf

Article Snippet:Antibody treatments and fibrinogen depletion Mice were given intraperitoneal injections of 2 μg/g body weight of anti-FXI antibody 14E11, 100 μg of monoclonal anti-GPIbα antibody 5A7, 200 μg of monoclonal anti-CD11b antibody M1/70, 100 μg of monoclonal anti-PSGL-1 (CD162) antibody, or the same doses of control IgG at 4 and 24 hours prior to the tumor cell inoculation.Mice were given intraperitoneal injections of 2 μg/g body weight of anti-FXI antibody 14E11, 100 μg of monoclonal anti-GPIbα antibody 5A7, 200 μg of monoclonal anti-CD11b antibody M1/70, 100 μg of monoclonal anti-PSGL-1 (CD162) antibody, or the same doses of control IgG at 4 and 24 hours prior to the tumor cell inoculation. ... Fibrinogen was depleted by intravenous injection of 25 KU/kg recombinant batroxobin (Creative BioMart, NY) from the snake venom of Bothrops atrox [ 31 ], 1 hour prior to tumor cell injection.. Fibrinogen depletion was monitored spectrophotometrically by absorbance changes at 350 nm of 100 μl of 10-fold diluted citrated plasma samples mixed with 100 μl of thrombin (100 nM).Fibrinogen depletion was monitored spectrophotometrically by absorbance changes at 350 nm of 100 μl of 10-fold diluted citrated plasma samples mixed with 100 μl of thrombin (100 nM).